These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Comparison between conventional surgery and radiotherapy for FIGO stage I-II cervical carcinoma: a retrospective Japanese study.
    Author: Yamashita H, Nakagawa K, Tago M, Shiraishi K, Nakamura N, Ohtomo K, Oda K, Nakagawa S, Yasugi T, Taketani Y.
    Journal: Gynecol Oncol; 2005 Jun; 97(3):834-9. PubMed ID: 15894366.
    Abstract:
    PURPOSE: To compare treatment outcome results of conventional surgery vs. radiotherapy (RT) for carcinoma of the uterine cervix. MATERIALS AND METHODS: A retrospective analysis was conducted of 152 patients with uterine cervical cancer radically treated with surgery or high dose-rate intracavitary brachytherapy (HDR-ICBT) with or without external RT from June 1991 to May 2004. The median follow-up time was 43.5 months (range, 1.0-130.0 months). The median age was 53 years (range, 25-81 years). There were 13 patients (9%) in stage IA, 52 (34%) in stage IB, 24 (16%) in stage IIA, and 63 (41%) in stage IIB. The conventional surgery group included 115 patients (76%) who underwent hysterectomy with pelvic lymph node dissection. Of these, 72 (63%) received postoperative radiotherapy. Thirty-seven patients (24%) were assigned to the RT group. Of these, 14 (38%) received chemoradiotherapy. Three patients with stage I received ICBT-alone without external beam irradiation. RESULTS: The 5-year cause-specific survival (CSS) rates for surgery and RT were 79.9% and 82.3%, respectively; the difference between these two treatments was not statistically significant (P = 0.8524). The differences in the survival rates between the two treatments for each of the stage I or stage II patients were also not statistically significant (P = 0.8407 for stage I and P = 0.6418 for stage II). CONCLUSIONS: This retrospective study suggests that RT results in compatible survival with conventional surgery for patients with stage I-II cervical carcinoma.
    [Abstract] [Full Text] [Related] [New Search]